CEP-9722

N/A

Report date: 2023/05/05 17:38:59
NME

Base Information

Drug NameCEP-9722
Drug Alias NameCK-102CEP-9722
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumoursLymphoma, Mantle-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTeva
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTeva Branded Pharmaceutical Products R&D IncCheckpoint Therapeutics IncCephalon
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphoma, Mantle-Cell

Other Information

ATC CodeN/A
Related LinksN/A